UnitedHealthcare’s Z-Code Requirement for Genetic Testing Claims Impacts Laboratories and Payers

UPDATE: 10/1/2024

UHC began phase 3 of the DEX Z-codes registration.

“Claims eligable for phase 3 tests with dates of service on or after Jan. 1, 2025, need to include the appropriate Z-Codes to be considered for reimbursement.” Genetic and pathology laboratories are urged to register with the Palmetto’s DEX® Diagnostics Exchange to ensure a chance at reimbursement on the list of CPT codes now reuqiring to be submitted with their corresponding Z-codes.

Visit the offical UnitedHealthcare DEX test code registry phase list for more information.

UPDATE: 1/2/2024

UHC announced that the policy requiring the use of Palmetto GBA’s DEX Z-codes will now be effective for dates of service on or after April 1, 2024. 

UHC outlines that claims for molecular pathology services will be denied if the DEX Z-code information is missing, invalid, or does not match the service represented by the CPT code reported on the claim. Denied claims may be resubmitted with required information to be considered for reimbursement. 

Visit the offical UnitedHealthcare Commercial Reimbursmeent Policy Update Bulletin and website for more information.

UPDATE: 10/3/2023

UnitedHealthcare (UHC) has made a recent policy reversal regarding genetic testing laboratories’ use of Z-codes for claims under commercial health plans. Initially, they postponed the enforcement date from August 1 to October 1, but they have since modified their guidance to be less specific about the compliance with Z-codes for genetic test claims. In a policy update on September 1, UHC announced that there is no fixed transition date for Z-codes anymore.

UHC has explained that they are delaying the policy to allow more time for providers to complete their molecular pathology test registrations for Z-codes. They will communicate the new policy date through network news before its publication.

UnitedHealthcare’s (UHC) recent announcement that it will require the use of Palmetto GBA’s DEX Z-codes for molecular diagnostic test services on facility and professional claims starting August 1, 2023, has triggered responses from genetic testing laboratories across the US. The enforcement of this requirement has been postponed to October 1, allowing labs more time to request their codes. This move by UHC not only affects genetic testing companies but also has implications for other private health plans.

The adoption of Z-code requirements is now a consideration for other health plans, thus raising questions of whether additional payers may implement their own Z-code requirements for genetic test claims and the potential timeline for doing so. This decision-making process reflects the competitive landscape among health plans. UHC’s stated motive behind this mandate is to improve patient outcomes and enhance efficiency in reimbursement processes. Genetic testing providers are concerned how the evolution of Z-code usage may add further challenges to obtaining timely reimbursement for these procedures. 

The emergence of Z-code policies reflects the challenges posed by the rapid growth of genetic testing and the inadequacy of Current Procedural Terminology (CPT) codes to keep pace. Genetic testing is now often intricately tied to pharmaceutical treatment plans, leading to increased complexities in billing and payment policies. Genetic testing labs frequently introduce new molecular assays, which further strains the capabilities of CPT codes to accurately represent these tests. Consequently, UHC’s Z-code requirement is expected to guide other major payers in devising similar solutions after observing UHC’s implementation.

Z-codes aim to address issues such as determining the appropriateness of genetic tests for a patient’s diagnosis, accurately measuring biomarkers, and ensuring effective patient outcomes. By scrutinizing claims and utilizing analytics, payers aim to spot irregularities and potential cases of fraud.  The goal to manage expenses while ensuring accurate testing has resulted in the need for improvement, or establishment, of efficient coding systems, potentially facilitated by use of Z-codes.

Although UHC’s policy might face resistance and external challenges, it is likely that the company, which has billions to invest in ancillary healthcare ventures, will follow through with its Z-code requirement, albeit with potential provider discontent. The approach and response to UHC’s mandate will serve as a model for other payers contemplating similar strategies. At-risk employers, who bear the financial burden of genetic testing claims, also have an interest in managing the cost of new and emerging testing procedures as they seek clarity and cost management in their health coverage offerings.

In conclusion, the surge in genetic testing claims has led both government and private payers to seek solutions for more effective reimbursement management. UnitedHealthcare’s adoption of Z-codes appears to be a concerted response to these challenges, influencing the industry toward similar strategies.

**References:**

– UnitedHealthcare announcement on Z-code requirement. https://www.uhcprovider.com/en/resource-library/news/2023/expanded-dex-z-codes-molecular-tests.html

– UnitedHealth Group Q2 earnings report.

https://www.unitedhealthgroup.com/newsroom/2023/2023-07-14-unh-second-quarter-results.html

– Reuters report on UnitedHealthcare’s acquisition of Amedisys. 

https://www.reuters.com/markets/deals/amedisys-agrees-unitedhealth-buyout-offer-scraps-option-care-deal-2023-06-26/#:~:text=June%2026%20(Reuters)%20%2D%20Home,with%20Option%20Care%20Health%20(OPCH.